Prokaryotics
Dr. Perlin is Chief Scientific Officer and Senior Vice-President of the Center for Discovery and Innovation and Professor of Medical Sciences at the Hackensack Meridian School of Medicine at Seton Hall University. His research emphasizes studies to diagnose and overcome drug-resistant fungal and bacterial infections by exploiting insights obtained from molecular investigations of drug resistance, pathogenicity, and host response to improve current therapies and develop novel drugs and diagnostics.
This person is not in the org chart
This person is not in any offices
Prokaryotics
Prokaryotics is a start-up biotechnology company resulting from licensing several novel antibiotic programs from Merck & Co., Inc. – by a team of former senior scientists at the company including the head of the Antimicrobial Early Discovery Unit, to optimize a number of Merck’s early-stage programs. Prokaryotics has negotiated worldwide rights to develop, manufacture and commercialize pre-clinical assets and programs targeting both Gram-negative and Gram-positive bacteria.